Natco Pharma launches generic of cancer drug in U.S.

Natco Pharma on with its spouse Breckenridge Pharmaceutical Inc has launched Pomalidomide Capsules, a generic mentation of Celgene’s Pomalyst successful the U.S. market.

A thalidomide analogue, the merchandise is indicated for the attraction of aggregate myeloma. It is besides approved for AIDS-related Kaposi sarcoma as good arsenic for HIV-negative big patients with Kaposi sarcoma.

NATCO said based connected accusation made disposable by the U.S. Food and Drug Administration (FDA) it believes that it has 180 days of shared exclusivity. Pomalidomide Capsules 1mg, 2mg, 3mg and 4mg had estimated income of $3.2 cardinal successful the U.S. for 12 months ending September 2025, the institution said, citing manufacture income data.

“The motorboat further strengthens our oncology and specialty portfolio successful the U.S. We look guardant to bringing much specified analyzable and specialty products to the marketplace successful the coming years,” Natco vice president and CEO Rajeev Nannapaneni said successful a merchandise connected Tuesday.